{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T16:27:55Z","timestamp":1780072075326,"version":"3.54.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"am","delay-in-days":351,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA057289"],"award-info":[{"award-number":["R01DA057289"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["U01DA051126"],"award-info":[{"award-number":["U01DA051126"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","ajpm-online.net","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Medicine"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.amepre.2024.03.014","type":"journal-article","created":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T00:15:43Z","timestamp":1711239343000},"page":"285-290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Illicitly Manufactured Fentanyl Use Among Individuals in the U.S., 2022"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8565-9415","authenticated-orcid":false,"given":"Joseph J.","family":"Palamar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amepre.2024.03.014_bib0001","series-title":"Drug overdose deaths: drug overdose deaths remained high in 2021","year":"2023"},{"issue":"4","key":"10.1016\/j.amepre.2024.03.014_bib0002","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/00952990.2022.2081923","article-title":"Trends in characteristics of fentanyl-related poisonings in the United States, 2015\u20132021","volume":"48","author":"Palamar","year":"2022","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1016\/j.amepre.2024.03.014_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109398","article-title":"Trends in seizures of powders and pills containing illicit fentanyl in the United States, 2018 through 2021","volume":"234","author":"Palamar","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.amepre.2024.03.014_bib0004","series-title":"Key substance use and mental health indicators in the United States: results from the 2022 National Survey on Drug Use and Health","year":"2023"},{"key":"10.1016\/j.amepre.2024.03.014_bib0005","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 5th ed., 2013, American Psychiatric Association; Washington, DChttps:\/\/psycnet.apa.org\/doi\/10.1176\/appi.books.9780890425596, Accessed April 2, 2024.","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"A","key":"10.1016\/j.amepre.2024.03.014_bib0006","article-title":"Characteristics of adults reporting illicitly manufactured fentanyl or heroin use or prescription opioid misuse in the United States, 2019","volume":"229","author":"Jiang","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"10.1016\/j.amepre.2024.03.014_bib0007","doi-asserted-by":"crossref","first-page":"202","DOI":"10.15585\/mmwr.mm7006a4","article-title":"Trends and geographic patterns in drug and synthetic opioid overdose deaths - United States, 2013\u20132019","volume":"70","author":"Mattson","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"474","key":"10.1016\/j.amepre.2024.03.014_bib0008","first-page":"1","article-title":"Co-involvement of opioids in drug overdose deaths involving cocaine and psychostimulants, 2011\u20132021","volume":"474","author":"Spencer","year":"2023","journal-title":"NCHS Data Brief"},{"issue":"50","key":"10.1016\/j.amepre.2024.03.014_bib0009","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.15585\/mmwr.mm7050e3","article-title":"Trends in and characteristics of drug overdose deaths involving illicitly manufactured fentanyls - United States, 2019\u20132020","volume":"70","author":"O'Donnell","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10","key":"10.1016\/j.amepre.2024.03.014_bib0010","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1111\/add.15458","article-title":"Heroin use cannot be measured adequately with a general population survey","volume":"116","author":"Reuter","year":"2021","journal-title":"Addiction"},{"key":"10.1016\/j.amepre.2024.03.014_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108416","article-title":"Fentanyl and fentanyl analogs in the illicit stimulant supply: results from U.S. drug seizure data, 2011\u20132016","volume":"218","author":"Park","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.amepre.2024.03.014_bib0012","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.drugpo.2017.05.023","article-title":"Exposure to fentanyl-contaminated heroin and overdose risk among illicit opioid users in Rhode Island: a mixed methods study","volume":"46","author":"Carroll","year":"2017","journal-title":"Int J Drug Policy"}],"container-title":["American Journal of Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379724001053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379724001053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T03:08:48Z","timestamp":1722049728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749379724001053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0749379724001053"],"URL":"https:\/\/doi.org\/10.1016\/j.amepre.2024.03.014","relation":{},"ISSN":["0749-3797"],"issn-type":[{"value":"0749-3797","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Illicitly Manufactured Fentanyl Use Among Individuals in the U.S., 2022","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amepre.2024.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}